Q2 2025 Outlook: Cautious Optimism Analyst consensus forecasts: Q2 EPS: $1.41 up 6% year-over-year Revenue: $20.73 billion slight increase of 0.2% YoY Over the past 30 days, EPS estimates have been revised upward by 0.53%, reflecting growing analyst confidence in the companys short-term outlook
The complete list of substances being removed from Category 2 is as follows: BPC-157 Cathelicidin LL-37 Dihexa Acetate Emideltide (DSIP) Epitalon GHK-Cu (for injectable routes of administration) KPV Mechano Growth Factor, Pegylated (PEG-MGF) Melanotan II MOTs-C Semax (heptapeptide) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) Of these, the substances not scheduled for consideration at the upcoming meeting in July (Cathelicidin LL-37, Dihexa Acetate, GHK-Cu (injectable routes of administration), Mechano Growth Factor Pegylated (PEG-MGF), and Melanotan II) are slated for separate PCAC consultation before the end of February 2027
Weeks 5 to 8 (maintenance phase): Structural tissue changes become more apparent
Types & Delivery Forms Youll See 1) Injectable (Subcutaneous or Intramuscular) Used in some sports-medicine and regenerative settings, often near the site of injury
Collagen Synthesis and Organization Collagen provides the structural framework for healing tissue
